The sociological concomitants of the pharmaceutical industry and medications

Handbook of Medical Sociology, Sixth Edition

Volumn , Issue , 2010, Pages 290-308

  Abraham, John ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857917299     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (101)

1. Abraham, John. 1994a. "Bias in Science and Medical Knowledge: The Opren Controversy." Sociology 28:717-36.
2. -. 1994b. "Distributing the Benefit of the Doubt: Scientists, Regulators and Drug Safety." Science, Technology and Human Values 19:493-522.
3. -. 1995a. "The Production and Reception of Scientific Papers in the Medical-Industrial Complex: Clinical Evaluation of New Medicines." British Journal of Sociology 46:167-90.
4. -. 1995b. Science, Politics and the Pharmaceutical Industry. London and New York: UCL/St. Martin's Press/Routledge.
5. -. 2002. "Transnational Industrial Power, the Medical Profession and the Regulatory State: Adverse Drug Reactions and the Crisis over the Safety of Halcion in the Netherlands and the UK." Social Science and Medicine 55:1671-90.
6. -. 2004. "Pharmaceuticals, the State and the Global Harmonisation Process." Australian Health Review 28:150-61.
7. Abraham, John, and Graham Lewis. 2000. Regulating Medicines in Europe: Competition, Expertise and Public Health. London: Routledge.
8. -. 2002. "Citizenship, Medical Expertise and the Capitalist Regulatory State in Europe." Sociology 36:67-88.
9. Abraham, John, and Julie Sheppard. 1999. The Therapeutic Nightmare: The Battle over the World's Most Controversial Sleeping Pill. London: Earthscan.
10. Angell, Marci. 2004. The Truth about Drug Companies. New York: Random House.
11. Applbaum, K. 2006. "Pharmaceutical Marketing and the Invention of the Medical Consumer." Public Library of Science Medicine 3:445-47.
12. Barkley, Russell. 1997. "Behavioral Inhibition, Sustained Attention, and Executive Functions: Constructing a Unifying Theory of ADHD." Psychological Bulletin 121:65-94.
13. -. 2003. "Attention-Deficit/Hyperactivity Disorder." In Child Psychopathology, ed. Russell Barkley and Eric Mash, 75-143. New York: Guildford Press.
14. BBC News 24. 1999. "Tough Guidance on Obesity Drugs." January 13. news.bbc.co.uk.
15. -. 2006a. "Herceptin: Was Patient Power Key?" June 9. news.bbc.co.uk.
16. -. 2006b. "Woman Wins Herceptin Court Fight." April 12. news.bbc.co.uk.
17. -. 2007. "Alzheimer's Drugs Remain Limited." August 10. news.bbc.co.uk.
18. Berenson, A. 2007. "Analysts See Merck Victory in Vioxx Deal." New York Times, November 10.
19. Bird, H., T. J. Yager, B. Staghezza, and M. S. Gould. 1990. "Impairment in the Epidemiological Measurement of Childhood Psychopathology in the Community." Journal of the American Academy of Childhood and Adolescent Psychiatry 29:796-803.
20. Blumberg, H. M., D. J. Carroll, and I. K. Wachsmuth. 1991. "Rapid Development of Ciprofloxacin Resistance in Methicillin-Susceptible and-Resistant Staphylococcus Aureus." Journal of Infectious Diseases 163:1279-85.
21. Bradley, J. S., R. Guidos, S. Baragona, and J. G. Bartlett. 2007. "Anti-Infective Research and Development-Problems, Challenges, and Solutions." Lancet Infectious Diseases 7:68-69.
22. Britten, Nicola. 2008. Medicines and Society. Basingstoke, Eng.: Palgrave.
23. Carpenter, Daniel P. 2004. "The Political Economy of FDA Drug Review: Processing, Politics and Lessons for Policy." Health Affairs 23:52-63.
24. Castellanos, X. 2002. "Development Trajectories of Brain Volume Abnormalities in Children and Adults with ADHD." Journal of the American Medical Association 288:1740-48.
25. Centre for Medicines Research. 2005. "Innovation on the Wane?" Latest News. www.cmr.org.
26. Code of Federal Regulations. 1992. "Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses." CFR Part 314, Subpart H.
27. Conrad, Peter, and Valerie Leiter. 2009. "From Lydia Pinkham to Queen Levitra: Direct-to-Consumer Advertising and Medicalization. " In Pharmaceuticals and Society: Critical Discourses and Debates, ed. Simon J. Williams, Jonathon Gabe, and Peter Davis, 12-24. Chichester, Eng.: Wiley-Blackwell.
28. Conrad, Peter, and D. Potter. 2000. "From Hyperactive Children to ADHD Adults." Social Problems 47:559-82.
29. Conrad, Peter, and J. W. Schneider. 1992. Deviance and Medicalization: From Badness to Sickness. Philadelphia: Temple University Press.
30. Cornwall, John. 1996. The Power to Harm: Mind, Murder and Drugs on Trial. Harmondsworth, Eng.: Penguin.
31. Couvoisie, H., and S. R. Hooper. 2003. "Neurometabolic Functioning and Neuro-Psychological Correlates in Children with ADHD: Preliminary Findings." Journal of Neuro-Psychiatry and Clinical Neuro-Sciences 16:63-69.
32. Daemmrich, Arthur, and Georg Krucken. 2000. "Risk versus Risk: Decision-Making Dilemmas of Drug Regulation in the U. S. and Germany." Science as Culture 9:505-34.
33. De Grandpre, R. 2000. Ritalin Nation: Rapid-Fire Culture and the Transformation of Human Consciousness. New York: W. W. Norton.
34. Diller, L. 1998. Running on Ritalin: A Physician Reflects on Children, Society and Performance in a Pill. New York: Bantam Books.
35. Drug Enforcement Administration. 2001. Aggregate Production Quota History, 1992-2002. Washington, D. C.: Department of Justice.
36. Edgar, H., and D. J. Rothman. 1990. "New Rules for New Drugs: The Challenge of AIDS to the Regulatory Process." Milbank Quarterly 68, suppl. 1:111-42.
37. Eli Lilly. 2000. Eli Lilly Annual Report 2000.
38. Epstein, Steven. 1996. Impure Science: AIDS, Activism, and the Politics of Knowledge. Berkeley: University of California Press.
39. FDA [Food and Drug Administration]. 1997. Modernization Act. Section 506 (b) (3) of the Food, Drug and Cosmetic Act (as amended by Section 112 of FDAMA). Washington, D. C.: GPO.
40. -. 2004. "Review and Approval Times for Priority and Standards NMEs." www.fda.gov.
41. -. 2009. "CDER Approval Times for Priority and Standard NMEs, 1993-2008." www.fda.gov/cder/rdmt/default.htm.
42. Ferriman, A. 1999. "Fat Is a Medical Issue." British Medical Journal 318:144.
43. Fleming, T. R. 2005. "Surrogate Endpoints and FDA's Accelerated Approval Process." Health Affairs 24:67-78.
44. Gale, E. A. M. 2001. "Lessons from the Glitazones." Lancet 357:1871.
45. Glenmullen, J. 2000. Prozac Backlash: Overcoming the Dangers of Prozac, Zoloft and Paxil and Other Antidepressants with Safe, Effective Alternatives. New York: Simon and Schuster.
46. Goldman, L. S., M. Genel, and R. J. Bezman. 1998. "Diagnosis and Treatment of ADHD in Children and Adolescents." Journal of the American Medical Association 279:1100-1107.
47. Grabowski, H., J. Vernon, and L. Thomas. 1978. "Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry." Journal of Law and Economics 21:133-63.
48. Harding, R. 2001. "Unlocking the Brain's Secrets." Family Circle, November 20, 10-11.
49. Healy, David. 2004. Let Them Eat Prozac. London: New York University Press.
50. -. 2006a. "The Latest Mania: Selling Bipolar Disorder." Public Library of Science Medicine 3:441-44.
51. -. 2006b. "The New Medical Oikumene." In Global Pharmaceuticals, ed. Adriana Petryna, Andrew Lakoff, and Arthur Kleinman, 61-84. Durham, N. C.: Duke University Press.
52. Herxheimer, Andrew. 2003. "Relationships between the Pharmaceutical Industry and Patients' Organizations." British Medical Journal 326:1208-10.
53. HCHC [House of Commons Health Committee]. 2005a. "Evidence" Nos. 354-56 in Proceedings of the Health Select Committee Hearings on Inquiry into the Influence of the Pharmaceutical Industry, January 20. London: TSO.
54. -. 2005b. Inquiry into the Influence of the Pharmaceutical Industry: Health Select Committee Report. London: TSO.
55. IMS Health. 2008. "Global Pharmaceutical Sales 2000-2007." imshealth.com/deployedfiles/imshealth/global/content/statcfile.pdf.
56. Infectious Diseases Society of America. 2004. Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, a Public Health Crisis Brews. Alexandria, Va.: ISDA.
57. International Society of Drug Bulletins. 2001. ISDB Declaration on Therapeutic Advance in the Use of Medicines, Paris, November 15-16.
58. Jeffries, M. 2000. "The Mark of Zorro." Pharmaceutical Marketing, May, 4-5.
59. Kaitin, Kenneth I., and J. Di Masi. 2000. "Measuring the Pace of New Drug Development in the User Fee Era." Drug Information Journal 24:673-80.
60. Kessler, David A., A. E. Hass, K. L. Feiden, M. Lumpkin, and R. Temple. 1996. "Approval of New Drugs in the U. S.: Comparison with the UK, Germany and Japan. " Journal of the American Medical Association 276:1826-31.
61. Kopelman, P. G. 2005. "Clinical Treatment of Obesity: Are Drugs and Surgery the Answer?" Proceedings of the Nutrition Society 64:65-71.
62. Krause, K-H., S. H. Dresel, J. Krause, C. La Fougere, and M. Ackervell. 2003. "The Dopamine Transporter and Neuro-Imaging in ADHD." Neuro-Science Bio-Behavioral Review 27:605-13.
63. La Revue Prescrire. 2005. "A Review of New Drugs in 2004: Floundering Innovation and Increased Risk-Taking." Prescrire International 14:68-73.
64. Lexchin, Joel, L. A. Bero, B. Djulbegovic, and O. Clark. 2003. "Pharmaceutical Industry Sponsorship and Research Outcomes and Quality." British Medical Journal 326:1167-70.
65. Mastro, T. D., J. S. Spika, R. R. Facklam, C. Thornberry, A. Ghafoor, N. K. Nomani, Z. Ishaq, F. Anwar, and D. M. Granoff. 1991. "Antimicrobial Resistance of Pneumococci in Children with Acute Lower Respiratory Tract Infection in Pakistan. " Lancet 337:156-59.
66. McCarthy, M. 2004. "The Economics of Obesity." Lancet 364:2169-70.
67. Medawar, Charles. 1992. Power and Dependence: Social Audit on the Safety of Medicines. London: Social Audit.
68. Medawar, Charles, and Anita Hardon. 2004. Medicines out of Control? Antidepressants and the Conspiracy of Goodwill. Amsterdam: Askant.
69. Mintzes, Barbara, M. L. Barer, R. L. Kravitz, K. Bassett, J. Lexchin, A. Kazanjian, R. G. Evans, R. Pan and S. A. Marion. 2003. "How Does Direct-to-Consumer Advertising (DTCA) Affect Prescribing? A Survey in Primary Care Environments with and without Legal DTCA." Canadian Medical Association Journal 169:405-12.
70. Mitka, M. 2003. "Accelerated Approval Scrutinized-Confirmatory Phase 4 Studies on New Drugs Languish." Journal of the American Medical Association 289:3227-29.
71. Moynihan, Raymond. 2006. "Obesity Task Force Linked to WHO Takes 'Millions' from Drug Firms." British Medical Journal 332:1412.
72. O'Donovan, Orla. 2007. "Corporate Colonization of Health Activism?" International Journal of Health Services 37:711-33.
73. O'Dowd, A. 2006. "More Than 12 Million Adults in En gland Will Be Obese by 2010." British Medical Journal 333:463.
74. O'Neill, P., and S. McIntosh. 1987. "Bacteria Resistant to Antibiotics Spread Concern. " New Scientist, August 27, 16.
75. Parsons, Talcott. 1951. The Social System. New York: Free Press.
76. Padwal, R. S., and S. R. Majumdar. 2007. "Drug Treatments for Obesity." Lancet 369:71-77.
77. Phillips, C. B. 2006. "Medicine Goes to School: Teachers as Sickness Brokers for ADHD." Public Library of Science Medicine 3:433-35.
78. Richards, T. 2008. "Border Crossing: Purely Medicinal?" British Medical Journal 336:693.
79. Roberts, T. G., and B. A. Chabner. 2004. "Beyond Fast Track for Drug Approvals." New En gland Journal of Medicine 351:501-3.
80. Schweitzer, S. O., M. E. Schweitzer and M-J. Sourty-Le Guellec. 1996. "Is There a U. S. Drug Lag? The Timing of New Pharmaceutical Approvals in the G-7 Countries and Switzerland." Medical Care Research and Review 53:162-78.
81. Scrip News. 1988. "Bush Calls for Speedier U. S. Approvals." Scripnews 1335:16.
82. -. 1995. "SSRIs-Unprecedented U. S. Growth." Scripnews 2020:23.
83. -. 1999. "Pfizer's Pharma Sales Soar 28%." Scripnews 2405:8.
84. Selgelid, M. J., and E. M. Sepers. 2006. "Patents, Profits, and the Price of Pills: Implications for Access and Availability." In The Power of Pills, ed. Jillian Clare Cohen, Patricia Illingworth, and Udo Schuklenk, 153-63. London: Pluto Press.
85. Sharma, V., J. M. Halpern, and J. H. Newcorn. 2000. "Diagnostic Co-morbidity, Attentional Measures, and Neuro-Chemistry in Children with ADHD." In Ritalin: Theory and Practice, ed. L. Greenhill and B. Osman, 15-24. Larchmont, Md.: Liebert.
86. Spellberg, B., J. H. Powers, E. P. Brass, L. G. Miller, and J. E. Edwards. 2004. "Trends in Antimicrobial Drug Development: Implications for the Future." Clinical Infectious Diseases 38:1279-86.
87. Talbot, G. H., J. Bradley, J. E. Edwards, D. Gilbert, M. Scheld, and J. G. Bartlett. 2006. "Bad Bugs Need Drugs: An Update on the Development Pipeline from the Anti-Microbial Availability Task Force of IDSA." Clinical Infectious Diseases 42:657-68.
88. Thambirajah, M. 1998. "Attention Deficit Hyperactivity Disorder in Children: Danger Is One of Over-Diagnosis." British Medical Journal 317:1250.
89. Timmerman, L. 2003. "Impotence Drug Cialis Gets OK for Sales in U. S." Seattle Times, November 22.
90. UK Department of Health. 1994. Prescription Cost Analysis. London: Government Statistical Service.
91. -. 2001. The Expert Patient-A New Approach to Chronic Disease Management for the 21st Century. London: HMSO.
92. -. 2003. Prescription Cost Analysis. London: Government Statistical Service.
93. U. S. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. 1984. Prescription Advertising to Consumers. Washington, D. C.: GPO.
94. Vallejo, J. G., S. L. Kaplan, and E. O. Mason. 1991. "Treatment of Meningitis and Other Infections due to Ampicillin-Resistant Haemophilus Influenzae Type B in Children. " Reviews of Infectious Diseases 13:197-200.
95. Van Klingeren, B., M. Dessens-Kroon, and M. Verheuvel. 1989. "Increased Tetracycline Resistance in Gonococci in The Netherlands." Lancet 334:1278.
96. Vos, Rein. 1991. Drugs Looking for Diseases: Innovative Drug Research and the Development of the Beta Blockers. Dordrecht, Netherlands: Kluwer.
97. Wardell, William. 1973. "Introduction of New Therapeutic Drugs in the U. S. and Great Britain: An International Comparison. Clinical Pharmacology and Therapeutics 14:773-90.
98. WHO [World Health Organization]. 2004. Priority Medicines for Europe and the World. Geneva: WHO.
99. -. 2006. "TRIPs and Pharmaceutical Patents." WTO Fact Sheet, 1-8. wto.org/english/tratop-E/TRIPS-e/factsheet-pharm00-e.htm.
100. Yuwiler, A., G. L. Brammer, and K. C. Yuwiler. 1994. "The Basics of Serotonin Neuro-Chemistry." In The Neuro-Transmitter Revolution: Serotonin, Social Behavior, and the Law, ed. R. Masters and M. McGuire, 37-46. Carbondale: Southern Illinois University Press.
101. Zametkin, A. J., T. E. Nordhal, M. Gross, A. C. King, W. E. Semple, J. Rumsey, S. Hamburger, and R. M. Cohen. 1990. "Cerebral Glucose Metabolism in Adults with Hyperactivity of Childhood Onset." New En gland Journal of Medicine 323:1361-66.